In final guidance NICE recommends Harvoni (ledipasvir+sofosbuvir) in hepatitis C- Gilead Sciences

In final guidance, NICE has recommended Harvoni (ledipasvir+sofosbuvir) from Gilead Sciences, as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. For hepatitis C without cirrhosis that has not been treated before, it recommends 8 weeks’ treatment and 12 weeks’ treatment for those who have been treated previously.

For hepatitis C with cirrhosis that has not been treated before, it recommends 12 weeks’ treatment and for those with cirrhosis who have been treated previously and fulfil specific conditions, it recommends 12 weeks’ treatment.

Comment: Harvoni offers advantages of a reduction of the complications found with interferon such as liver cirrhosis and is likely to encourage compliance and a reduction in transmission of the disease.